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Abstract: Cyanovirin-N (CV-N) is an antiviral lectin with potent activity against enveloped viruses,
including HIV. The mechanism of action involves high affinity binding to mannose-rich glycans
that decorate the surface of enveloped viruses. In the case of HIV, antiviral activity of CV-N is
postulated to require multivalent interactions with envelope protein gp120, achieved through a
pseudo-repeat of sequence that adopts two near-identical glycan-binding sites, and possibly involves
a 3D-domain-swapped dimeric form of CV-N. Here, we present a covalent dimer of CV-N that
increases the number of active glycan-binding sites, and we characterize its ability to recognize four
glycans in solution. A CV-N variant was designed in which two native repeats were separated
by the “nested” covalent insertion of two additional repeats of CV-N, resulting in four possible
glycan-binding sites. The resulting Nested CV-N folds into a wild-type-like structure as assessed
by circular dichroism and NMR spectroscopy, and displays high thermal stability with a Tm of
59 ˝C, identical to WT. All four glycan-binding domains encompassed by the sequence are functional
as demonstrated by isothermal titration calorimetry, which revealed two sets of binding events to
dimannose with dissociation constants Kd of 25 µM and 900 µM, assigned to domains B and B’ and
domains A and A’ respectively. Nested CV-N displays a slight increase in activity when compared to
WT CV-N in both an anti-HIV cellular assay and a fusion assay. This construct conserves the original
binding specifityies of domain A and B, thus indicating correct fold of the two CV-N repeats. Thus,
rational design can be used to increase multivalency in antiviral lectins in a controlled manner.
Keywords: Cyanovirin-N; antiviral lectins; glycan-binding proteins; oligomannose; gp120
1. Introduction
Cyanovirin-N (CV-N) is a small (11 kDa) cyanobacterial protein with potent antiviral activity
towards HIV, Ebola, influenza, hepatitis C, and other enveloped viruses [1–5]. Its mechanism of action
involves high affinity binding to the oligomannose glycans tethered to the viral envelope glycoproteins,
gp120 in the case of HIV. The CV-N solution structure [1–6] shows an unique beta sheet fold that
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comprises two quasi-symmetric glycan binding sites, A (residues 1–38/90–101) and B (residues 39–89),
connected on each side by a short helical linker. Each carbohydrate binding site binds Man (1Ñ 2)Man
termini in oligomannose selectively, although domain B binds dimannose more tightly than domain A,
and domain A shows selectivity for linear trimannose [1–5,7]. Computational and mutational studies
have clarified the contribution of sequence to specificity in the two sites [6,8–13]. Site B consists of a
contiguous stretch of amino acids, whereas N- and C-terminal residues fold to form glycan binding site
A. This unique configuration results in possible dimerization by 3D domain swapping of the CV-N fold,
which occurs under some conditions through the extension of a hinge region (residues 50–53), resulting
in the creation of four carbohydrate-binding sites A, A´ and B, B´ that retain glycan selectivity [14–19].
It has been shown that the 3D domain swapped dimer is a kinetically trapped folding intermediate.
Conversion of the domain-swapped dimeric form to the thermodynamically stable monomer is slow
in physiological conditions [18,19]. However, interconversion is fast in the conditions used to assay
antiviral activity; thus, an accurate comparison of the activity of these forms has been challenging.
The role of multivalency, e.g., the presence of at least two binding domains, for the antiviral
activity of CV-N is well established; however, it remains unclear whether activity can be enhanced
beyond that of WT by further increasing the number of binding domains [16,19–24]. Mutations
resulting in inactivation of either site A (P51G-m4-CV-N) [19] or site B (CV-NmutDB) [24] cause a
significant decrease in binding affinity for gp120 by ELISA and completely eliminate antiviral activity.
The crucial role of multivalency for WT activity was demonstrated by the restoration of antiviral
activity upon forced dimerization of these defective variants, either through mutations that induced
3D domain swapping [21] or through engineered disulfide linkages [25]. These results show that at
least two binding sites are necessary for antiviral activity, regardless of the identity of the domains [26].
Two approaches have been taken to probe whether the activity of WT CV-N could be further enhanced
by engineering constructs with more than two binding domains, yielding contradictory results.
Stable domain-swapped forms of CV-N obtained through hinge region mutations (∆Q50)CV-N and
(S52P)CV-N display antiviral activity identical to that of WT CV-N, despite comprising four glycan
binding domains instead of two [18]. However, a series of covalent dimers of CV-N show 3- to 18-fold
enhancement of antiviral activity over the monomeric WT CV-N. These proteins were designed to
stabilize the 3D domain swapped dimer by connecting two CV-N sequences through polypeptide
linkers of varying length, and fold into a rigid structure resembling the 3D domain-swapped dimer
as verified by X-ray crystallography [22]. Surprisingly, further increasing the number of glycan
binding sites by linking more than two CV-N sequences in tandem did not increase antiviral activity.
The rigid domain swapped arrangement of the CV-N repeats, though, raises the question of whether
the enhancement of activity is limited by steric issues that may prevent simultaneous engagement
of more than two sites, due to geometric constraints in binding oligomannose displayed on the viral
surface [22].
In this work, we introduce a novel covalent dimer as platform to address multivalency and
geometric requirements. The design is inspired by natural CV-N homologous proteins, and contains a
flexible dimer of CV-N meant to avoid steric constraints and rigidity intrinsic to 3D domain swapping
could confer enhanced antiviral activity. To accomplish this, we engineered a novel dimeric CV-N
construct, dubbed Nested CV-N, which is built by splicing a second CV-N sequence within the two
repeats of a first one. We show that Nested CV-N forms a stable, well folded dimer as designed,
with secondary structure content and thermal stability comparable to WT CV-N, and no evidence of
oligomer formation. Further, Nested CV-N possesses enhanced binding affinity to gp120 and activity
against HIV slightly increased compared to WT. These results support our hypothesis that enhanced
antiviral activity derives from multivalency, and that flexible constructs may allow optimal orientation
of carbohydrate binding domains on the target gp120 glycoprotein.
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2. Materials and Methods
2.1. Protein Expression and Purification
A synthetic gene encoding for Nested CV-N and containing a pelB leader sequence at the start
and a His-tag sequence at the C terminus (GenScript, Piscataway, NJ, USA) was double digested with
NdeI and XhoI, and ligated into pET26b(+) vectors using established protocols. The vectors were
transformed into NEB5α cells and BL-21(DE3) cells (New England Biolabs, Inc., Ipswich, MA, USA).
Protein expression was carried out as previously described [19,27].
The proteins were obtained from the periplasmic fraction, and purified by nickel affinity
chromatography (Ni Sepharose High Performance medium, GE Healthcare, Marlborough, MA, USA),
using 400 mM imidazole under native conditions for the elution step. Molecular mass and purity were
confirmed by Tricine SDS-PAGE gel and by MALDI-TOF mass spectrometry. Amino acid analysis was
used to determine extinction coefficients at 280 nm (assay performed at NCI). Protein concentrations
were determined by measuring tryptophan absorbance at 280 nm using the experimentally verified
extinction coefficient of 19,540 M´1 cm´1.
2.2. Circular Dichroism Spectroscopy (CD)
Circular Dichroism (CD) measurements were performed using a Jasco J-815 spectropolarimeter
equipped with a thermostatic cell holder, PTC 424S. Spectra were measured from 240 to 190 nm, using a
scanning speed of 50 nm/min and a data pitch of 1.0 nm at 15 ˝C [28]. Samples contained approximately
15 µM of protein in 10 mM HEPES, pH = 8.0 buffer. Thermal denaturation was monitored on full
spectra collected every 2 ˝C in the 4 to 90 ˝C temperature range. Detailed thermodynamic analysis
was precluded due to the irreversible unfolding of Nested CV-N, which reflects the behavior of WT
CV-N [29]. Apparent Tm was determined by analyzing the sigmoidal curves recorded at 235 nm using
commercially available software (Prism 6, GraphPad Software).
2.3. Chemical Denaturation Analysis
Chemical denaturation titrations were performed on pre-equilibrated samples due to the slow
folding kinetics of CV-N and its mutants [29]. For each concentration of GdnHCl, a sample containing
10 M protein in 20 mM NaPO4 buffer, pH 7.5 was incubated at room temperature for 72 h. The
concentration of GdnHCl in each sample was verified by refractometry. Equilibrium denaturation
curves were determined both by monitoring the circular dichroism signal as described above, and
by monitoring the intrinsic tryptophan fluorescence; the excitation wavelength was set to 290 nm,
and fluorescence emission was collected from 300 to 400 nm. Denaturation curves were obtained
by plotting I330/I360 tryptophan fluorescence ratio for each sample versus Gdn¨HCl concentration.
The I330/I360 was obtained for each point by exciting at 290 nm and recording emission at 330 and
360 nm for 1 min [29]. The apparent midpoint of the transition for each curve was determined using
commercially available software (Prism 6, GraphPad Software, San Diego, CA, USA).
2.4. Isothermal Titration Calorimery
Isothermal titration calorimetry (ITC) was performed at the Sanford-Burnham Medical Research
Institute Protein Analysis Facility using a ITC200 calorimeter from Microcal (North Hampton, MA,
USA). The data were analyzed using Origin software package provided by Microcal. Two separate
conditions were used to measure binding of dimannose to Nested CV-N. First, 3.6 mM dimannose
was titrated into 100 µM Nested CV-N in 20 mM HEPES for high affinity binding site determination
(data not shown). This data were fitted to “one set of sites” model since contribution from low affinity
sites was relatively small at these conditions. This measurement experimentally confirmed presence of
2 high-affinity binding sites for dimannose in Nested CV-N. To characterize the low affinity binding
sites we have titrated 20 mM dimannose into 100 µM Nested CV-N. The data were fitted to “two set
of sites” model to accommodate both low and high affinity binding sites. Thermodynamic values
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obtained for the high affinity binding sites from the 3.6 mM dimannose titration were used to initialize
parameters for the fitting of 20 mM dimanose data. Due to low C value for the low affinity sites, we
were not able to determine stoichiometry for the low affinity binding experimentally. However, ITC
data are consistent with 2 high/2 low affinity sites per Nested CV-N. To characterize binding of Man9,
1 or 2 mM Man9 was titrated into 20 and 30 µM Nested CV-N, respectively, in 20 mM HEPES. Only
one set of sites (4 sites having the same high affinity) was detected for Man9.
2.5. Nuclear Magnetic Resonance
1H-15N HSQC spectra were recorded on a 150 µM Nested CV-N sample uniformly enriched
in 15N at 14.1T on a Bruker Avance III 600 spectrometer equipped with a Prodigy triple resonance
probe, at 312 K with 256 scans per increment, 640 (t2) ˆ 70 (t1) complex points with acquisition
times of 76 ms (1H) and 63 ms (15N). NMR data processing was carried out using NMRPipe [30] and
subsequently analyzed by visual inspection compared to wild type CV-N chemical shift assignments
using NMRViewJ [31,32].
2.6. Binding to gp120
Binding of Nested CV-N to glycosylated soluble gp120 was assessed by enzyme-linked
immunosorbent assays (ELISA), using WT CV-N as internal reference [33,34]. Each well of a 96-well
plate (Nunc; Maxiscorp, Gaithersburg, MD, USA) was incubated with 100 ng of gp120 (rgp 120 HIV-1
MN, baculovirus; ImmunoDiagnostics, Inc. Woburn, MA, USA) or ribonuclease B in phosphate
buffered saline (PBS) for two hours at room temperature. The plates were then rinsed with PBS
containing 0.1% Tween 20 (PBST) three times, and blocked by treatment with 3% bovine serum albumin
(BSA) at 4 ˝C overnight. The plates were then washed three times with PBST. Half log serial dilutions of
Nested CV-N and WT CV-N were then added to the wells in triplicate, for final concentrations ranging
from 0.005 nM to 0.05 µM. The last column was left as a blank, and only contained the BSA. The plates
were incubated for one hour and washed three times with PBST. Bound proteins were detected with
His-tag targeting reagents. The plates were incubated with 100 µL/well of the HisProbe-HRP (1 µg/mL
in PBS-T) (Thermo Scientific, Waltham, MA USA) for 1 h at room temperature. After the plates were
washed three times with PBS-T, 100 µL/well of tetramethylbenzidine peroxidase substrate solution
(KPL) was added and incubated ~2 min. The reaction was quenched with 100 µL of 2 M H2SO4 and
the absorbance at 450 nm was read.
2.7. Antiviral Assays
Cellular viability assay. The anti-HIV activity of Nested CV-N and Nested-P CV-N were assessed
in the Molecular Targets Laboratory, NCI at Frederick using a modified XTT assay that measures the
cytopathic effect of HIV-1 on CEM-SS cells. Briefly, uninfected CEM-SS cells were plated at a density
of 1 ˆ 10´5 cells/mL in 50 µL of complete medium in a 96-well plate. Serial dilutions of 100 µL of
CV-N as standard and Nested CV-N were added to the wells. The cells were then infected with 50 µL
of HIV-1RF virus. The plates were incubated at 37 ˝C in an atmosphere containing 5% CO2 for 6 days.
To estimate cellular viability, 50 µL XTT solution was added to each well and incubated for 4 h at
37 ˝C. Cells that had not been killed by the HIV virus could reduce XTT to a soluble, colored formazan
while HIV-infected and subsequently lysed cells could not. Metabolic reduction of XTT to formazan
was recorded by absorbance at 450 nm to determine cellular viability. CV-N and variant samples
were thawed to room temperature, mixed, and diluted into PBS pH 7.4 at the specified submitted
concentration. A total of 2, 60 µL aliquots were submitted for each sample to obtain quadruplicate data
points. The samples were serially-diluted using a 100.5 dilution scheme, and HIV induced cytopathicity
evaluation was conducted as described [35].
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2.8. Cell Fusion Assay
BSC-40 cells (ATCC) and TZM-bl cells (NIH AIDS Research and Reference Reagent Program
Division of AIDS, NIAID, NIH: from John C. Kappes, Xiaoyun Wu and Tranzyme Inc., Durham, NC,
USA) [36,37] were seeded in flasks [both in DMEM (Cell Gro, #10017CV), supplemented with 10%
FBS (Fisher-Scientific, Waltham, Massachusetts, USA) for TZM-bl and 5% FBS for BSC-40 cells] and
infected when confluency was reached. BSC-40 cells were infected with vTF7-3 (obtained through the
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: from Tom Fuerst and Bernard Moss) [38]
and vCB41 (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: from
Christopher C. Broder, Paul E. Kennedy, and Edward A. Berger), each at an MOI of 3. TZM-bl cells
were infected with vCB21R-LacZ (obtained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH: from Christopher C. Broder, Paul E. Kennedy, and Edward A. Berger) [39] virus at an
MOI of 3. Infected cells were incubated for 18 h at 32 ˝C, then were disrupted with Cell Dissociation
Buffer (Gibco, Billings, MT, USA). DMEM supplemented with 2.5% FBS was used to dilute proteins,
and 160 µL of each dilution was transferred to a well of a 96-well plate. Each cell line, at 4 ˆ 104 cells,
was added to the wells containing inhibitor. Controls were wells with only one cell line and no protein,
wells with both cell types but no protein, and wells with medium only (no cells or protein). The plate
was then incubated at 37 ˝C for 2.5 h, and then frozen at ´80˝. On the day of the assay, the plate
was thawed, and 10 µL of 10% NP40 was added to each well and mixed by pipetting. The plate was
incubated at room temperature for 20 min. Fifty microliters of each sample was transferred to a fresh
plate. Fifty microliters of room temperature 2ˆ CPRG (Genlantis, San Diego, CA, USA) was added to
each well containing a sample. The plate was read at 570 nm (BioTek, uQuant, Winooski, VT, USA) as
soon as any well began to show color change.
3. Results
3.1. Design of Nested CV-N
We designed Nested CV-N after Type III CV-NH family members in which the two glycan binding
sites of cyanovirin are separated by the insertion of a distinct protein domain (LysM). This suggested
that it might be possible to increase ligand multivalency by inserting a second cyanovirin sequence
(101 amino acids) in the linker region between the two glycan binding sites (Figure 1). The sequence
of Nested CV-N thus starts with amino acids 1–50, which comprise part of site A (1–39) and site B
(40–50), followed by a linker (G8), and residues 59–162, which comprise a complete CV-N structure
(sites A’ and B’), a second linker (GGSGGGGS), and finally residues 173–222, which complete the folds
of site B (173–210) and site A (211–222). The full sequence is reported in Supplemental Information
(Appendix A) (Figure A1). Based on the structure of a Type III CV-NH protein [40], two cyanovirin
domains can be viewed as ellipsoids that are predicted to be nearly orthogonal to each other, creating
a tight control of the spatial arrangement of each domain (Figure 1A). Nested CV-N contains two
copies of domain A (A, A’) and two copies of domain B (B, B’); as in WT CV-N, the domains are not
contiguous in the sequence (Figure 1B). The inserted sequence of CV-N contains a P51G mutation,
thus preventing possible formation of domain-swapped dimers. Compared with the rigid structure
of the domain-swapped dimers, the flexible linkers connecting the two CV-N units should permit
an increased flexibility of the binding domains that we hypothesized might affect engagement with
glycosylated gp120. Using the NMR structure of WT CV-N bound to two dimannoses (PDB entry
1IIY) [41] as a template, we docked dimannose in each of the four glycan-binding domains of Nested
CV-N (Figure 1). According to our model, the distances between the four binding sites on Nested
CV-N range between approximately 15 Å (B-B’) and 45 Å (A-A’), with A-B distances approximately
30 Å; for comparison, distances in the 3D domain-swapped dimer of WT CV-N are in the 30–35 Å
range [22,42]. Thus, the Nested CV-N construct should be able to accommodate a broader array of
glycan presentation on the surface of gp120.
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one and connected by flexible linkers. 
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from the design; the profile displays no evidence of aggregation supporting the use of the P51G 
substitution to prevent oligomerization (Figure A2). To determine whether Nested CV-N was well 
folded, we evaluated circular dichroism (CD) and NMR data. The CD spectrum of Nested CV-N 
displays a minimum at approximately 212 nm and a maximum around 192 nm (Figure A3), features 
consistent with the presence of mainly β-sheet structure, and closely resembles that of WT CV-N and 
of P51G-m4-CV-N, indicating that the overall backbone CV-N fold is conserved in Nested CV-N 
[19,43]. We assessed the thermodynamic stability of Nested CV-N to chemical and thermal 
denaturation by monitoring the CD signal as a function of either [Gdn·HCl] or temperature. A 
rigorous analysis of folding parameters obtained from thermal or chemical denaturation is not 
possible beyond apparent values, since thermal denaturation of CV-N and its mutants is not fully 
reversible, and chemical denaturation proceeds through at least one folding intermediate [29]. 
However, direct comparison of the apparent midpoints of the transitions with WT CV-N reveals 
comparable stability. The thermal denaturation profile of Nested CV-N monitored at a wavelength 
of 235 nm (Figure 2) shows an apparent Tm of 59.0 °C, identical to that of WT CV-N measured in 
similar conditions [21]. Chemical denaturation profiles were obtained by equilibrating samples 
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Figure 1. Model of Nested Cyanovirin-N (CV-N): Top panel, glycan binding domains A and A’ are in
blue and B and B’ in red; docked dimannose is represented in yellow. The two CV-N folds are enclosed
in ellipsoids to highlight the structures (dashed lines). Bottom panel, Sequence arrangement of WT
CV-N and designed Nested CV-N construct; as in WT CV-N, the binding domains are not contiguous
in the sequence. The sequence of one CV-N protein is spliced into the sequence of a second one and
connected by flexible linkers.
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CV-N is a monomer as assessed by gel filtration chromatography: the elution profile contains a single
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We assessed the thermodynamic stability of Nested CV-N to chemical and thermal denaturation by
monitoring the CD signal as a function of either [Gdn¨HCl] or temperature. A rigorous analysis of
folding parameters obtained from thermal or chemical denaturation is not possible beyond apparent
values, since thermal denaturation of CV-N and its mutants is not fully reversible, and chemical
denaturation proceeds through at least one folding intermediate [29]. However, direct comparison of
the apparent midpoints of the transitions with WT CV-N reveals comparable stability. The thermal
denaturation profile of Nested CV-N monitored at a wavelength of 235 nm (Figure 2) shows an
apparent Tm of 59.0 ˝C, identical to that of WT CV-N measured in similar conditions [21]. Chemical
denaturation profiles were obtained by equilibrating samples containing identical concentration of
protein and [Gdn¨HCl] in the 0-6 M range at room temperature for 72 h prior to CD readout at
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215 mn [29]. The apparent midpoint of the transition Cm is 2.4 M for Nested CV-N, identical to that of
WT CV-N (Figure A4).
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We turned to NMR spectroscopy to provide site-specific information on whether Nested CV-N
is folded throughout its sequence. The 1H-15N HSQC spectrum gives rise to excellent chemical shift
dispersion in both dimensions, indicating the absence of local unfolded structure (Figure 3). Nested
CV-N comprises 230 residues, which would typically give rise to over 230 crosspeaks in the HSQC
spectrum if its tertiary structure consisted of a single domain. In contrast, we observe ~167 crosspeaks
(excluding sidechain resonances), which might arise from either intermediate exchange or from a
subset of residues existing in magnetically equivalent environments giving rise to a single crosspeak.
This latter idea is consistent with the design of Nested CV-N, which comprises two structurally
equivalent CV-N repeats (Figure 1). To evaluate this possibility, we compared wild type CV-N and
Nested CV-N spectra and found some residues appear to give rise to a single crosspeak, whereas other
residues appear to give rise to two or more crosspeaks with similar chemical shifts. We interpret these
data to reflect that some residues in Nested CV-N adopt a unique chemical environment identical to
wild type CV-N, whereas other residues adopt slightly different chemical environments resulting in
crosspeak doubling. In some cases the linewidths from these crosspeak pairs differed significantly
enough to suggest different protein dynamics between the Nested domains. To further evaluate this
possibility, we tentatively assigned 40% of the Nested CV-N spectrum from visual inspection of the
monomeric wild type CV-N spectrum. Chemical shift assignments from 44 out of 110 wild type CV-N
residues could be transferred to the Nested spectrum with reasonable confidence. Of these 44 residues,
10 resulted in two crosspeaks for each residue (T7, Q14, L48, N30, L36, D44, W50, A70, G96, T97)
including residues involved in both the high and low affinity binding sites. Thus, no correlation
between structure and crosspeak doubling was apparent eliminating the possibility that the observed
conformational heterogeneity derived from a specific interface. We conclude that the Nested CV-N
construct adopts the intended fold albeit with slight differences in structure and dynamics between
the two CV-N repeats.
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3.3. Binding to Glycans and Antiviral Activity
We evaluated the functional integrity of the glycan-binding domains comprised within Nested
CV-N by analyzing its ability to bind dimannose, as well as complex oligomannosides (Man-5 through
Man-9) displayed on protein surfaces. The structures of the complex Man-9 and Man-8 glycans contain
M (1Ñ 2)Man termini, one of which is also part of a linear trimannose (the D3, D2, and D1 arms),
and thus can satisfy the bindi g requireme ts of domains A and B; in Ma -8, the central D2 arm is
missing one mannose unit; smaller oligomannosides contain Man (1 Ñ 2)Man termini [44]. To this
end, we first asse sed binding of Nested CV-N to di annose (Man (1 Ñ 2)Man and to Man9 in
solution by isothermal titration calorimetry (ITC). The data are shown in Figure 4. Titratio with
dimannose revealed the presence of two sets of binding sites, one with high affinity and one with
low affinity, each with a stoichiometry of two. Analyses of the binding events yields Kd = 25 ˘ 2 mM
and Kd = 950 ˘ 8 µM, respectively (see Methods for details). The dissociation constants for the two
sites are comparable to those obtained for WT CV-N, which also contains a high-affinity binding site
(Kd = 15.3 µM) and a low-affinity one (Kd = 400 µM). These results are consistent with NMR-monitored
titrations by which the high affinity site was assigned to domain B, and the lower affinity site to domain
A [11,41]. In contrast, binding to Man-9 involves four sites, each with Kd = 1.10 ˘ 0.07 µM; the four
sites appear indistinguishable, possibly because the differences in binding affinities within the two
type of domains are too small for detection, or because the presence of both dimannose and linear
trimannose in the Man-9 structure satisfies the intrinsic glycan preference of each domain. This value
is comparable with the dissociation constant of 0.488 ˘ 0.071 µM reported for 1:1 binding of WT CV-N
to Man-8 [20].
Binding of Nested CV-N to complex oligomannosides on protein surfaces was assessed using
ELISA on immobilized gp120 and ribonuclease B (Figure 5). Ribonuclease B contains a single
N-linked glycosylation site, populated with a mixture of Man-5, Man-6, Man-7, Man-8 and Man-9
isoforms [45,46]. Previously, we have shown that WT CV-N recognizes Man-8 and Man-9 isoforms
on the surface of ribonuclease B, but not the other smaller isoforms. ITC measurements revealed
that binding to Man-8 with a 1:1 stoichiometry and a sub-micromolar dissociation constant [34]. The
assays were conducted in parallel with WT CV-N as internal control; to avoid possible differences
in affinity with available anti-CVN antibodies, the proteins were detected with HRP-conjugated
His-tag specific reagents as described in Methods. We found that Nested CV-N interacts with both
glycoproteins with apparent affinity comparable to WT CV-N. The EC50 values for binding to gp120
are 1.29 ˘ 0.11 ˆ 10´9 M for Nested CV-N and 1.66 ˘ 0.35 ˆ 10´9 M for WT CV-N. Testing with
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ribonuclease B resulted in very similar EC50 values of 1.3 ˘ 0.1 ˆ 10´8 M and 1.7 ˘ 0.2 ˆ 10´8 M
respectively for Nested CV-N and for WT CV-N. As observed before, binding to ribonuclease B is
slightly weaker compared to binding to gp120, because only a portion of the ribonuclease B bound to
the ELISA plate actually bears either Man-8 or Man-9. Furthermore, ribonuclease B contains a single
glycosylation site for CV-N binding, whereas gp120 contains about 25 sites per monomer [34,44].
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Having assessed the ability of Nested CV-N to bind glycans with high affinity, we evaluated its
anti-HIV activity using a modified XTT-tetrazolium assay. This assay measures cell viability when
exposed to infective HIV virions in the presence of increasing concentrations of added inhibitor, over a
period of one week at 38 ˝C [36]. Nested CV-N was compared to WT CV-N from two source laboratories
and to P51G-CVN, which contains the same hinge region mutations present in the central CV-N repeat
in Nested CV-N. The P51G mutation stabilizes the monomeric version of CV-N, and disfavors the
formation of the 3D domain-swapped form by increasing the energy barrier for the interconversion
between the two forms. We found that the activity of Nested CV-N is slightly increased compared to
that of WT CV-N, showing 2-5 fold improvement compared to WT CV-N, and approximately 8 times
compared to P51G-CVN; all proteins are active at sub-nanomolar concentrations. The EC50 values
are shown in Table 1. We further confirmed these data by assessing the ability of Nested CV-N to
block viral entry into target cells. This assay evaluates the inhibition of HIV-mediated cell fusion,
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using a vaccinia virus-based gene reporter system adapted from the procedure developed by Berger
and colleagues [37]. We found that Nested CV-N exhibited inhibitory activity similar to WT CV-N,
as shown by IC50 values of 7.5 ˘ 0.6 nM and 18 ˘ 0.5 nM, respectively (Table 1).
Table 1. Glycan binding and anti-HIV-1 activity of Nested CV-N and WT CV-N.
Protein Binding to gp120EC50 (nM)
Antiviral Activity
EC50 (nM)
Fusion Inhibition
IC50 (nM)
Nested CV-N 1.29 ˘ 0.11 0.1 ˘ 0.02 7.5 ˘ 0.6
WT CV-N 1.66 ˘ 0.35 0.2 ˘ 0.04 18 ˘ 0.4
WT CV-N (MTL) a N/A 0.5 ˘ 0.08
P51G-CVN 4 b 0.8 ˘ 0.04
a A second wild-type CV-N control produced in the Molecular Targets Laboratory. All sample quantities were
determined by amino acid analysis. b From Reference [18].
These data provide further support to a correlation between number of functional glycan-binding
domains and antiviral activity for CV-N. P51G-CVN, which is found exclusively as a monomer upon
incubation at 38 ˝C, should present only two binding domains in the conditions of the assay, and it is
the least active of the series. Nested CV-N, which contains four functional glycan binding modules as
confirmed by ITC, shows the highest activity. WT CV-N, which can access both the monomeric and
the 3D domain swapped form, shows intermediate activity.
4. Conclusions
We adopted the domain architecture of Type III CV-N homologous family (CV-NH) proteins to
design Nested CV-N, predicted to contain two independently folded CV-N structures connected by
linkers, providing enhanced multivalency. Nested CV-N appears to adopt the intended fold comprising
two near identical WT CV-N repeats. The two-dimensional NMR spectrum demonstrates that many of
the Nested residues exhibit identical or near-identical chemical shifts indicating that these residues
experience identical chemical environments. Further, Nested CV-N is stable to thermal denaturation,
and contains four functional dimannose binding domains, two with high affinity and two with low
affinity as assessed by ITC, consistent with the presence of two sets of domains as observed in WT CV-N.
The difference in affinity between the two domains is lost when Nested CV-N is assayed with Man9,
which comprises both linear dimannose and trimannose and thus can satisfy the glycan recognition
specificity of each domain [9,26,47]. Affinity for Man9, which more closely resembles the complex
glycans found on protein surfaces, is higher than for dimannose (approx. 1 µM compared with 25 µM
and 900 µM for dimannose). The advantage conferred by the presence of multiple glycan-binding
domain is also seen in binding to heavily glycosylated proteins: compared to sparsely glycosylated
ribonuclease B, Nested CV-N binds gp120 with EC50 at 10 times lower concentrations. The activity of
Nested CV-N against HIV in cellular assays is comparable to that of WT CV-N: A slight increase of 2–5
fold observed may indicate that all binding domains are engaged simultaneously, and will be further
investigated. We note that the activity of Nested CV-N is enhanced 8-fold compared to P51G-CVN,
which cannot form domain swapped dimers. The increase in activity observed with Nested CV-N was
confirmed in fusion inhibition assays using indicator cells.
Over the years, the relationship between multivalency and antiviral potency in antiviral lectins
has been the object of vigorous investigation. Through the use of site directed mutagenesis it was
established that at least two intact glycan binding sites are necessary for the antiviral activity of CV-N,
but it remained unclear whether the activity could be augmented over that of WT CV-N by augmenting
the number of domains [19,21,24,25,27]. Our results confirm the importance of multivalency in the
antiviral activity of CV-N, and support the development of flexible covalent dimers as a means to
simultaneously engage all four glycan-binding sites. The robustness of the CV-N fold to reengineering
of its glycan binding sites[11,29,48] may lead to future designs built on Nested CV-N that further
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augment its activity and/or modulate its specificity, and which could be used as specific recognition
modules for glycans.
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